-
1 Comment
From a valuation standpoint, the stock is 98.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 19.6.
Based on the above factors, 4D Molecular Therapeutics, Inc gets an overall score of 1/5.
ISIN | US35104E1001 |
---|---|
Industry | Biotechnology |
Sector | Healthcare |
CurrencyCode | USD |
Exchange | NASDAQ |
Market Cap | 567M |
---|---|
Dividend Yield | 0.0% |
Target Price | 38.14 |
PE Ratio | None |
Beta | 2.57 |
4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform. It develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has product candidates that are in clinical trials, such as 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease cardiomyopathy. Its product candidates also include 4D-150 for the treatment of wet age-related macular degeneration and diabetic macular edema; and 4D-710 for the treatment of cystic fibrosis lung disease. In addition, the company has two product candidates that are in preclinical development stage, such as 4D-175 for the treatment of geographic atrophy; and 4D-725 for the treatment of alpha-1 antitrypsin deficiency lung disease. It has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for FDMT using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024